Wereport a rare case of complete remission for 32 months with continuous treatment with alltrans retinoic acid (ATRA)alone in a patient with acute promyelocytic leukemia which developed as a second malignancy after the treatment of osteosarcoma after failure of conventional chemotherapy. The adverse effects of ATRA were apparently tolerable. (Internal Medicine 33: 654-657, 1994) 
Introduction
Sixty-four or 96% of patients with acute promyelocytic leukemia (APL) enter complete remission upon treatment with all-trans retinoic acid (ATRA) (1 , 2) . However, the duration of complete remission is generally brief, and relapse occurs despite continuous ATRAtreatment (1, 2). Wereport a rare patient with APL,second malignancy after the treatment of osteosarcoma, whohad been in complete remission (CR) for 32 months with the continuous treatment of ATRA alone after failure of conventional chemotherapy.
Case Report
A 13-year-old male who developed osteosarcoma at the right distal femur underwent excision and replacement of the right knee joint in August 1987. At the age of 14 (15; 17) . Westarted induction therapy with enocitabine at 300 mg/day x 10 days, daunorubcin at 70 mg/day x 7 days, 6-mercaptopurine at 100 mg/day x 10 days, and prednisolone at 60 mg/day x 4 days, as well as therapy for DIC with gabexate mesilate from G-CSF å¡ April 10, 1991 (Fig. 1) . However, this treatment caused severe bone marrow hypoplasia. He developed cerebral bleeding and sepsis. Recombinant humangranulocyte colony stimulating factor was used for the bone marrowrecovery but increased the APLcell number, and the induction regimen was therefore considered to be ineffective. ATRAat a dose of 90 mg/day was used as alternative induction therapy from April 28, 199 1 , and the patient was also receiving gabexate mesylate for DICand antibiotics for sepsis. As he developed hyperleukocytosis (WBC; 31,18O/|il) and jaundice, ATRA was discontinued on May 8, 1991, and Ara-C at 80 mg/day was administrated for 2 days to counter hyperleukocytosis. After 2 days, when the value of total bilirubin began to decrease, ATRAtherapy at 60 mg/day was begun again from May 17, 1991. After5 days ofATRA therapy DIC was improved. After 29 days of ATRAtherapy, in June 1991 , he entered complete remission. The karyotype of bone marrowcell chromosomesbecamenormal 29 days after the initial ATRAtreatment. The patient, whohad been on maintenance therapy with ATRAat 40 mg/day, had been in CR and healthy for 32 months. APL relapsed in February 1994.
Discussion
After the induction into complete remission with ATRA, it was not replaced with conventional chemotherapy as postremission chemotherapy because the patient's liver and renal function was impaired and because the first induction chemotherapy regimen had been ineffective. He had received multiple high doses of chemotherapeutic agents for osteosarcoma, including 675 mg/m2of ADR.As we were concerned about the cumulative effect of anthracycline (3), we did not consider conventional chemotherapy but rather opted to continue ATRA as maintenance therapy. APLpatients maintained with ATRA alone have been reported to relapse earlier and have poor sensitivity to ATRAafter relapse ( 1 , 2) . However, in the present very rare case, our patient had been in CRwith ATRAalone for about 32 months. Although the plasma ATRAlevel is reported to be reduced in the ATRA-resistant patient with APL, the mechanism of reduction is not known (4). Although the plasma ATRA level in our patient wasnot examined, wespeculate that his poor liver function may contribute to high the plasma level of ATRA.
The development of leukemia as a second malignancy after treatment of a childhood malignancy is well known, but its 1}the interval between onset of osteosarcoma and acute leukemia.
2)NR: no response, CR: complete remission. 3)47,XX,+8,t(9; l l) (9 metaphases); 48,XX,+8,+13,t(9; l l) (8 metaphases); 46,XX,t(9; l l)(p21;q23) (7 metaphases). 4)47,XY,+6,t(4;l l)(q21;q23) (6 metaphases); 47,XY,+6,t(l;8)(p36;ql3),t(4; l l)(q21;q23) (6 metaphases).
incidence varies with the type of primary tumor. The relative risk ratio of leukemia for a patient whose primary tumor is Hodgkin's disease is 89 and 8.3 forosteosarcoma (5-10). Thus, leukemia in a patient with osteosarcoma as the primary tumor is relatively rare, with only a few cases having been reported (1 1-14) ( Table 2 ). Secondary APLsare relatively rare and occupy only 1 and 4. 1 %of all secondary leukemia after chemotherapy and/or radiotherapy for Hodgkin's disease and all malignant disease, respectively (15, 16) . The present case is the first reported case to our knowledgein a patient with APL related to chemotherapy for osteosarcoma. The median duration from the treatment of the first tumor until the development of therapy-linked leukemia is generally 4-5 years, but that in patients with osteosarcoma as the first tumor is 30 months ( Table 2 ). In the present patient, this interval was 4 years. In addition to alkylating agents and procarbazine originally postulated to be leukemogenic drugs, etoposide was suggested as a causal relationship with secondary acute myelocytic leukemia (17) (18) (19) (20) . The characteristics of secondary acute myelocytic leukemia after etoposide treatment are reported to be: 1) a shorter latency period (2-3 years), 2) lack of a preleukemic phase, 3) more frequent occurrence ofFAB subtype M4or M5, and 4) peculiar cytogenetic constitution (often involving 1 Iq23 translocation). Hauptet al reported the first case of secondary APL (variant type) after single-agent chemotherapy with etoposide for Langerhans' cell histiocytosis of bone (21). Our patient had been treated with 300 mg/m2 of etoposide. The relationship with etoposide and secondary AML,especially APLmay require further investigation. Since the treatment of osteosarcoma has recently becomemore intensive in an effort to improve survival, therapy-linked acute myelogenousleukemia may become a more frequent complication. This possibility should be considered in patients with osteosarcoma whodevelop unexplained pancytopenia after receiving combined modality therapy.
